R. S. Lavey, P. Y. Liu, B. E. Greer, et al., “Recombinant Human Erythropoietin as an Adjunct to Radiation Therapy and Cisplatin for Stage IIB-IVA Carcinoma of the Cervix: A Southwest Oncology Group Study,” Gynecologic Oncology, Vol. 95, No. 1, 2004, pp. 145-151. doi:10.1016/j.ygyno.2004.07.009

has been cited by the following article:

• TITLE: Prognostic Impact of Carcinoembryonic Angtigen (CEA) in Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy

  AUTHORS: Kiyosumi Shibata, Hiroaki Kajiyama, Mik Mizuno, Eiko Yamamoto, Fumitaka Kikkawa

  KEYWORDS: Cervical Cancer; Chemoradiotherapy; Recurrence; Prognostic Factor; Carcinoembryonic Angtigen (CEA)

  JOURNAL NAME: Surgical Science, Vol.3 No.10, October 18, 2012

  ABSTRACT: Objective: To identify prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy (CCRT). Methods and Materials: We analyzed 76 patients with FIGO stage IB2 - IVb cervical cancer treated with CCRT between 2001 and 2006 at the Nagoya University Hospital. Patients with an advanced cervical cancer treated with CCRT. Overall survival (OS) and Progression-free survival (PFS) rates were estimated using the Kaplan-Meier method. The log-rank test was used to test differences in survival. Fisher's exact test was employed for univariate analysis. The Cox proportional hazard model was used for multivariate analysis. Results: The median age was 52, and the median follow-up period was 36 months. The 5 - year OS and PFS rates of all patients were 88.2% and 72.4%, respectively. Twenty-one of the 76 patients were diagnosed with recurrence. A higher serum CEA before CCRT was an independent predictive factor for a poor prognosis on multivariate analysis. Conclusions: A high level of serum CEA was a predictive factor for a poor prognosis. New strategies should be considered to control disease in this group of patients.